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Abstract: Antimalarial drugs will be essential tools at all
stages of malaria elimination along the path towards
eradication, including the early control or ‘‘attack’’ phase
to drive down transmission and the later stages of
maintaining interruption of transmission, preventing
reintroduction of malaria, and eliminating the last residual
foci of infection. Drugs will continue to be used to treat
acute malaria illness and prevent complications in
vulnerable groups, but better drugs are needed for
elimination-specific indications such as mass treatment,
curing asymptomatic infections, curing relapsing liver
stages, and preventing transmission. The ideal malaria
eradication drug is a coformulated drug combination
suitable for mass administration that can be administered
in a single encounter at infrequent intervals and that
results in radical cure of all life cycle stages of all five
malaria species infecting humans. Short of this optimal
goal, highly desirable drugs might have limitations such
as targeting only one or two parasite species, the
priorities being Plasmodium falciparum and Plasmodium
vivax. The malaria research agenda for eradication should
include research aimed at developing such drugs and
research to develop situation-specific strategies for using
both current and future drugs to interrupt malaria
transmission.
Introduction
Antimalarial drugs are used to treat malaria illness, to prevent
both infection and disease caused by Plasmodia, to eliminate
dormant malaria parasites from the liver, and to prevent malaria
transmission. In the context of malaria elimination or eradication,
drugs have been used for both treatment and prevention in
situations where intensive surveillance has been used to identify
cases, and in mass drug administration (MDA) programmes
without regard for the presence of infection.
The malERA Drugs Consultative Group brought together
malaria biologists, drug developers, clinical investigators, and
control officials, and consulted outside experts on drug develop-
ment and disease eradication to identify and prioritize a
preliminary set of knowledge gaps and research questions that
need to be addressed to use drugs effectively along with other tools
to eliminate and ultimately eradicate malaria. The consultative
process was predicated on several key assumptions, and included a
review of the role of drugs in past and recent elimination
campaigns.
Several current research questions were identified that should
be high priorities whether or not malaria eradication moves
forward. However, the main work of the group was to draft a
research and development agenda that focuses on those new
research questions and knowledge gaps that arise specifically in
response to the call for malaria eradication and that would not
otherwise be at the top of the malaria research agenda. Thus, new
and better drugs for intermittent preventive treatment (IPT) of
malaria in pregnancy and molecular markers that can be used as
surveillance tools for monitoring artemisinin-resistant malaria are
both critically important research priorities, but are not specific to
the malaria eradication agenda, and are not discussed in this
paper.
In this paper, ‘‘eradication’’ refers to the interruption of
transmission and fall in disease incidence to zero worldwide,
‘‘elimination’’ refers to interruption of transmission and a fall in
disease incidence to zero in a defined geographical area, and
‘‘control’’ refers to reduction of disease incidence and burden to
the point where it is no longer a public health priority.
Starting Assumptions
The thinking of the malERA Drugs Consultative Group was
based on the assumption that malaria eradication is not possible
with existing tools, which include artemisinin-based combination
treatments (ACTs), long-lasting insecticide-treated nets, and
insecticide spraying. It is true that with this set of tools, dramatic
reductions in malaria have been achieved recently in many
countries, including some in Africa [1]. Malaria has even been
completely eliminated from some areas with low levels of
transmission and relatively sound health care infrastructure by
the World Health Organization (WHO) Global Malaria Eradica-
tion Program and by more recent elimination efforts [2].
However, it is the view of the malERA Drugs Consultative Group
that complete global malaria eradication will not be accomplished
within most of our lifetimes, and that new tools, including new
antimalarial drugs developed specifically for elimination indica-
tions, are essential to move towards and ultimately achieve this
ambitious but eminently worthy goal. Our thinking was also
predicated on the assumption that these new tools will need to be
used in combinations with each other.
Review articles synthesize in narrative form the best available evidence on a topic.
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critical fact that eradication entails the complete elimination of any
latent or persistent parasite reservoir in the human population.
The complex life cycles of the five malaria species infecting
humans present different challenges. Malaria parasites can persist
for years without causing symptoms, both in the liver (in the case
of P. vivax and Plasmodium ovale), and in the blood (Plasmodium
malariae), and low-level infections that cannot be detected by
standard diagnostic methods can nevertheless propagate transmis-
sion. Eradication of targeted malaria species is therefore likely to
require drugs that can accomplish complete ‘‘eradication’’ of every
malaria parasite from the bodies of infected humans, including
those who are carrying very low levels of parasites that cause no
symptoms but that might be a source of transmission. Moreover,
we anticipate that eradication tools are likely to become
increasingly compromised by the emergence and spread of drug-
resistant [3] and ‘‘vaccine-resistant’’ parasites [4] and of
insecticide-resistant mosquitoes [5], and we recognize that tools
and approaches that were successful in settings with reasonably
intact health care systems, functioning governments, and accessi-
ble populations, will be inadequate for the elimination of malaria
in the hardest-to-reach and most unstable corners of the malaria-
endemic world.
Moreover, although insecticides are appropriately credited for
much of the success of the first global eradication campaign
carried out in the mid-20th century, careful review of malaria
control and elimination efforts shows that treatment and
prevention with drugs have also been essential components of all
successful malaria elimination schemes. Similarly, although
smallpox has been eradicated and polio nearly so primarily
through the use of vaccines, for reasons elucidated elsewhere [6],
including the partial and temporary nature of naturally acquired
protective immunity to malaria, and the need to eliminate latent
infections that persist in the face of natural immunity, it is very
unlikely that malaria could be eradicated with even a highly
efficacious vaccine without concomitant use of drugs and
antivector methods. The notion that a single silver bullet in the
form of one brilliant technological advance could spell the end of
the single biggest killer of human beings for thousands of years is
appealing, but borders on magical thinking. We fervently hope to
be proven wrong on this point, and strongly encourage young
scientists to pursue brilliant technological advances and silver
bullets, but believe that investment in a variety of complementary
tools is needed.
Another of our starting assumptions was that although the
current scheme for malaria elimination described in the Global
Malaria Action Plan [7] calls for the elimination stage to begin
when control efforts result in a reduction in malaria incidence to
,1 case/1,000 population at risk, malERA should consider
research questions related to the possible role of new and old drugs
at all stages of malaria control and elimination. In particular, the
role of drugs in aggressive efforts to drive down high transmission
rates during the control phase of eradication—formerly and
perhaps more inspirationally called the ‘‘attack’’ phase—should be
considered. For example, drugs might be used in mass screening
and treatment or MDA campaigns, or as ongoing IPT intended to
reduce both morbidity and transmission.
Finally, we assumed that incipient elimination and eradication
efforts will likely focus initially chiefly on P. falciparum in Africa, but
that P. vivax will be a major focus outside of Africa, where it is the
most common form of malaria. P. vivax causes more morbidity,
severe disease, and death than is often appreciated [8]. It also
presents special challenges because of the relapsing liver-stage
parasites (hypnozoites) that are refractory to treatment with most
antimalarial drugs, and it will increase in prominence as rates of
falciparum malaria decrease. We therefore assumed that research
and development will proceed in parallel to develop drugs that can
be used to eliminate P. falciparum and P. vivax, ideally drugs that
target both species, although better species-specific drugs are also
likely to make a great contribution. Eventually, the other human
malarias, P. malariae, P. ovale, and Plasmodium knowlesi, may have to
be considered as specific targets for global eradication as their
impact is modified by control or elimination of the other species,
although it is hoped that these minority species will be eliminated
in a collateral fashion by tools aimed at falciparum and vivax
malaria.
What’s New about the Approach to Drugs in the
Context of Elimination?
In the first malaria eradication campaign, antimalarial drugs
were considered for their role in eliminating infection in people
and thus reducing the infectious reservoir. Subsequently, there was
a reorientation towards thinking about controlling malaria as a
disease rather than as an infection, with more emphasis on
preventing clinical complications and death [9]. There was less
concern about curing infection in settings where rapid re-infection
was guaranteed. To prepare for a long-term approach to
elimination, it is necessary to revive the earlier paradigm and
again think about malaria drugs and other interventions in terms
of their impact on malaria infection and transmission in addition
to their use in the prevention and treatment of malaria disease.
‘‘Elimination thinking’’ also underlies the concept of adding anti-
gametocytocidal drugs to the treatment of malaria in areas such as
Cambodia [10] where resistance to ACT drugs is being observed
[11,12].
Current Drug Indications
We identified several high priority research areas that need to
be addressed urgently regardless of whether the world mobilizes
for a renewed effort to eliminate malaria. The first such area is
optimization of the use of ACTs and other currently available
antimalarial drugs to maximize their useful lifespan. Approaches
to achieve this optimization include the rational design of drug
combinations with well-matched pharmacokinetic and pharmaco-
dynamic profiles, operational research to increase uptake of
coformulated ACTs while minimizing the use of artemisinin
monotherapy and suboptimal dosing, and the evaluation of
strategies to reduce relative pressure for emergence and dissem-
ination of resistance [13,14].
The second high priority area is continued research and
development to make new drugs available to replace current drugs
(in particular, artemisinins) as resistance emerges. Specific
priorities include first-line drugs for treating uncomplicated
falciparum and vivax malaria, drugs to treat severe malaria, drugs
for IPT of infants, pregnant women and children, drugs for travel
chemoprophylaxis, and anti-relapse drugs to cure the liver stages
of P. vivax.
Research is also needed to elucidate the pharmacokinetics and
pharmacodynamics and optimal dosing of drugs used to treat and
prevent malaria, especially in understudied vulnerable groups
including pregnant women, young children and infants, as is
operational research and research into improved diagnostics, and
into monitoring to optimize drug deployment strategies and
facilitate control efforts using currently available antimalarial
drugs.
Although malERA’s charge was to identify new research
questions and knowledge gaps that arise in response to the call
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example, maintaining the development pipeline of first-line drugs
to treat uncomplicated falciparum malaria—will have to be
addressed for eradication to succeed. But, while it is extremely
important that this pipeline continues to flow whether or not
global malaria eradication is being attempted, the malERA Drugs
Consultative Group did not focus on defining the optimal
characteristics of drugs for treating this or other clinical malaria
syndromes. Instead, we focused on drugs that would be needed
specifically for the purposes of eradication, noting, for example,
the need for widespread use (possibly in whole asymptomatic
populations) of drugs with better safety profiles than would be
required for treatment of individuals with potentially life-
threatening clinical malaria.
New Drug Indications in the Context of Eradication
Table 1 lists the current indications for antimalarial drugs, and
considers the relevance of these for the specific goal of malaria
eradication. For example, suppressive prophylaxis, which prevents
malaria disease but that does not prevent and may even augment
transmission, is not a relevant indication for malaria eradication.
It is reasonable to assume that drugs that target P. falciparum will
generally be effective against P. malariae, and that those targeting
P. vivax will be efficacious against P. ovale and P. knowlesi. This
assumption is based on limited experience with current drugs, and
should be tested by routinely including patients infected with these
minority species in drug trials. No single trial would include
enough cases of the minority species to provide a meaningful
measure of efficacy, but pooling data from many trials using a
global database such as the Worldwide Antimalarial Resistance
Network (WWARN; www.wwarn.org) [15] would, over time,
permit estimation of efficacy of commonly used drugs against these
species. Importantly, the recent identification of the monkey
malaria P. knowlesi as a widespread and potentially life-threatening
human pathogen [16] suggests that vigilance for transfer of other
nonhuman primate malarias to humans and the determination of
which drugs are effective against these emerging diseases may be
necessary in the late stages of elimination.
Lessons Learned from Past Malaria Elimination
Programmes and Efforts to Eradicate Other
Diseases
As a matter of priority, experienced malariologists need to
dedicate substantial time and effort to detailed analytical reviews
of published and unpublished information on past elimination
efforts. Here we briefly summarize a few of the insights gained
from malERA reviews of some of the available material, including
a dissection of the Global Malaria Eradication Program [17], and
a broad overview of lessons learned from past malaria elimination
efforts published by the Malaria Elimination Group [18]. In
particular, we note the need for a much more comprehensive
review of the use of drugs in past elimination efforts, which
includes careful analysis of factors leading to success or failure (see
Table 2).
Importance of Single-Encounter Therapy
For smallpox, the only infectious disease that has been
eradicated, a single-dose vaccine was available that could emulate
the lifelong protective immunity that results from natural infection.
Similarly, the drugs that are presently being used in large-scale
infectious disease control and elimination programmes such as
those for onchocerciasis and trachoma can be administered in a
single encounter once or twice a year. Discussions with leaders of
these campaigns highlighted the notion that single-encounter
interventions are an essential requirement for successful elimina-
tion campaigns. Notably, however, the antimalarial drug regimens
that were used with varying success to eliminate malaria from Italy
[19], the former Soviet Union [20], and various islands such as the
Vanuatu island of Aneityum [21], have involved complex
regimens of multiple administrations of at least two drugs usually
repeated at frequent intervals for prolonged periods of time. We
Table 1. Indications for antimalarial drugs in the present control era and their relevance in the eradication era.
Indications for Antimalarial Drugs in the Control Era Relevant to Malaria Eradication?
Prophylaxis
Causal prophylaxis
a Yes, completely blocks infection and thus transmission
Suppressive prophylaxis
b No, does not prevent, and may augment, transmission
IPT of pregnant women, infants, or children Maybe, but only if transmission-blocking drugs are used in a high proportion of the
infected reservoir, essentially amounting to intermittent MDA
Treatment of disease
Uncomplicated malaria
P. falciparum and P. malariae Maybe, treatment indications for specific clinical syndromes are not directly relevant
to the goal of eradication unless treatment drugs have transmission-blocking efficacy;
widespread use of treatment drugs with antiliver stage and gametocytocidal activity
would contribute to transmission reduction.
P. vivax and P. ovale As above
Severe malaria As above
Antihypnozoite (liver-stage radical cure) Yes, high priority
Transmission blocking Yes, high priority
aCausal prophylaxis targets pre-erythrocytic liver stages and, if effective, prevents any parasites from reaching the blood state or being transmitted to mosquitoes.
bSuppressive prophylaxis is repeated subcurative dosing that suppresses blood-stage infection and prevents malaria illness but does not eradicate malaria infection or
prevent transmission
doi:10.1371/journal.pmed.1000402.t001
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multiple drugs have been used successfully to eliminate malaria
from areas with relatively good health systems and stable
populations, malaria eradication will require drugs that, ideally,
can be administered in a single encounter at infrequent intervals
(see Box 1).
Mass Drug Administration
MDA refers to the use of drugs to treat whole populations for
malaria, irrespective of, and without knowledge of, who is infected
[22]. Although this approach is not currently recommended,
antimalarial drugs have been used in MDA campaigns since at
least 1900, when subsidized and free quinine was distributed by
the Italian government for both suppressive prophylaxis and
curative treatment [19]. Suppressive prophylaxis reduces the risk
of acute malaria illness by controlling the level of infection without
ridding the body of parasites; curative treatment resolves an acute
malaria illness episode by eliminating all asexual blood-stage
malaria parasites and may or may not result in a fully sterilizing
cure; both approaches may either prevent, augment, or have no
effect on transmission to mosquitoes. The Italian MDA campaign
resulted in large decreases in malaria cases and mortality but not
interruption of transmission [19]. Malaria was only finally
eliminated in Italy when DDT spraying was aggressively deployed
after World War II in combination with systematic diagnosis and
quinine treatment and mass quinine prophylaxis.
In the former Soviet Union, mass chemoprophylaxis with blood
schizonticides (drugs that kill the blood-stage malaria parasites that
cause disease but that do not usually affect either liver-stage
parasites or the sexual stage gametocytes that transmit malaria to
the mosquito) was administered each year at the peak of the
malaria season during the attack phase of elimination, then phased
out during the ‘‘consolidation’’ phase as the last remaining foci of
transmission were extinguished [20]. As malaria transmission risk
coalesced into localized ‘‘islands’’ of risk, the entire local
population was given both a blood schizonticide and an 8-
aminoquinoline 2–3 weeks before the start of the malaria season.
8-aminoquinolines are active against gametocytes as well as
against P. vivax and P. ovale relapsing liver forms; examples of 8-
aminoquinolines include plasmocide and quinocide (now super-
seded drugs that were used in the USSR), the widely used and
licensed primaquine, and tafenoquine, which is still investigational.
Other examples of MDA campaigns include the Garki Project
in Nigeria, where simultaneous spraying and MDA significantly
but only transiently reduced malaria parasite prevalence rates
[23]. Similarly, mass chemoprophylaxis of a million soldiers used
in conjunction with insecticide-treated nets and spraying resulted
in the near-elimination of vivax malaria where it had reemerged
20 years after the Korean demilitarized zone had been declared
malaria free [24]. Most recently, mass administration of
artemisinin, piperaquine, and primaquine in Cambodia resulted
in dramatic reductions in the prevalence of P. falciparum, P. vivax,
and P. malariae, including a 10-fold reduction in the prevalence of
falciparum gametocytes, but not the complete interruption of
transmission [10]. Often, these schemes were implemented with
no clear idea of what the MDA programme was trying to achieve,
and in many cases political or economic factors were major drivers
[22]. However, the main factors that are common to successful
MDA schemes include a careful preparatory phase, social
mobilization, improvement of the health care infrastructure and
the inclusion of malaria control in comprehensive health care, and
the concomitant use of antivector measures.
Another common success factor is that MDA (like other malaria
elimination efforts) is more likely to work where malaria risk is
circumscribed, such as on sea islands or in ‘‘islands’’ of malaria risk
surrounded by areas with no malaria. Sustained interruption of
falciparum and vivax malaria transmission was achieved in 1996
Table 2. Past use of drugs in malaria elimination.
How Drugs Were Used in Elimination General Assessment
Curative therapy for cases detected through surveillance Essential component of all successful control and elimination programmes
Intensive, multidrug, multidose MDA used in conjunction with aggressive antivector
interventions (nets, spraying, larvicides)
Contributed to several successful elimination programmes
Less intensive MDA as a complement to less aggressive or subsequent antivector
interventions
Limited, transient, or no success at elimination
MDA as the main elimination measure Successful only in a few cases of isolated, stable populations
Medicated salt Mixed success and major drawbacks of danger of rapid selection for
resistance and safety issues
doi:10.1371/journal.pmed.1000402.t002
Box 1. Single Encounter Radical Cure and
Prophylaxis (SERCaP)
Currently, the goal of antimalarial drug therapy is to
reduce disease and death by targeting blood-stage
parasites, with an emphasis on falciparum malaria in
young children in Africa. This goal is accomplished by
prompt diagnosis and treatment of fever with effective
drugs such as ACTs. For eradication to be effective, drug
therapy must eliminate the human reservoir of infection,
an objective that is best achieved by Single Encounter
Radical Cure and Prophylaxis (SERCaP). Achieving the
objective in a single patient encounter is important for
effectiveness. Radical cure is defined as eliminating all
parasites in the patient; eradication of the disease on a
population basis can only be achieved by ‘‘eradication’’ of
the parasites in all individuals. For P. falciparum, this entails
the elimination of all persistent asexual blood-stage forms,
and the long-lived mature-stage V P. falciparum gameto-
cytes that are responsible for transmission. For P. vivax
malaria, radical cure includes elimination of all persistent
asexual blood-stage forms, and the long-lived hypnozoites
in the liver. Finally prophylaxis highlights the need to
prevent reinfection of each individual treated for some
defined period after treatment. This time should be at least
for 1 month, to outlast the typical development period of
Plasmodium parasites in Anopheline mosquitoes.
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regimen consisting of weekly chloroquine and primaquine for 9
weeks, sulfadoxine-pyrimethamine at weeks 1, 5, and 9, and
concomitant use of insecticide-treated nets and larvicides [21]. A
less intensive MDA regimen using three drugs at two-monthly
intervals followed by DDT spraying at the end of the campaign
had no measurable impact on overall malaria prevalence on the
island of Zanzibar [25], highlighting the need to deploy multiple
interventions aggressively and simultaneously to interrupt trans-
mission. Where there are large areas of contiguous malaria risk, as
in much of sub-Saharan Africa, the effectiveness of MDA has been
transient at best. However, high transmission intensity does not
necessarily preclude successful use of MDA; rather, high
transmission often signifies contiguity with surrounding areas of
malaria risk, with inevitable back-flow of infections unless MDA
and other interventions are applied widely and simultaneously
across the entire area of contiguous risk through transnational
cooperation, another factor that is common to successful MDA
programmes.
Finally, although MDA in the form of adding antimalarial drugs
to salt used for cooking and flavoring food had some success in
reducing malaria prevalence in large-scale pilot programmes in
Asia, Africa, and South America [26], the inability to control
dosage and the resulting rapid selection for drug-resistant parasites
make this an unjustifiable approach [22].
Long-Acting Formulations
Another creative approach from the past that may hold promise
for the future is the use of long-acting formulations. ‘‘Repository’’
formulations of malaria drugs to provide prolonged protection
were extensively researched in the early 1960s [27], and oil-based
depot injections of cycloguanil pamoate provided more than 1
year of protection against experimental challenge with P.
falciparum sporozoites [28]. These injections were evaluated in
at least 15,000 people, but never deployed as a tool for elimination
because of the attendant pain and local abscesses.
Key Knowledge Gaps and Research Priorities
On the basis of this initial review of past and present malaria
control and elimination efforts, the malERA Drugs Consultative
Group concluded that antimalarial drugs will be essential
components for elimination of malaria from endemic countries
and eventually for worldwide eradication. In the next step of our
discussions, we identified the key knowledge gaps about the role of
drugs in malaria eradication and research priorities for developing
and using drugs in malaria elimination and eradication pro-
grammes. We organized these knowledge gaps into three areas: (1)
the optimization of the use of currently available drugs for
elimination and eradication; (2) the development of new drugs for
elimination and eradication; and (3) the development of drug
Box 2. A Draft Research and Development Agenda for Drugs for Malaria Eradication
KNOWLEDGE GAPS AND RESEARCH PRIORITIES FOR OPTIMIZING CURRENT
DRUGS
N Pharmacology studies to optimize dosing regimens of 8-
aminoquinolines for gametocytocidal and anti-relapse
efficacy and safety
N Rapid and robust point-of-care glucose-6-phosphate de-
hydrogenase (G6PD) test to improve safety of 8-amino-
quinoline use
N Tests that can detect resistance to artemisinins and ACT
partner drugs
N Determine gametocytocidal and anti-relapse activity of
current drugs and those in the pipeline
KNOWLEDGE GAPS AND RESEARCH PRIORITIES FOR DEVELOPING NEW
DRUGS FOR MALARIA ERADICATION
Desired products
N Drugs that prevent transmission by killing or preventing
development of gametocytes, or blocking sporozoite
development in the mosquito
N Drugs that cure liver stages of vivax (and ovale) malaria
N Ideally, drugs that can be administered in a single
encounter at infrequent intervals, and that result in radical
cure of all parasite stages (Single Encounter Radical Cure
and Prophylaxis, see Box 1)
N Sustained or pulsed release formulations
N Exceptionally safe schizonticidal drugs for curing asymp-
tomatic falciparum infection
Fundamental research questions aimed towards develo-
ping desired drugs
N Fundamental studies of liver and sexual stage biology (in
both host and mosquito)
N Mechanisms of resistance and pharmacological strategies
to deter resistance
N In vitro culture of P. vivax to understand parasite biology
Tools and capacities
N Increased capacity for clinical pharmacology research
including pharmacokinetics/pharmacodynamics studies in
populations targeted for malaria elimination
N Increased capacity for human challenge studies for early
go/no go decisions on drug candidates
N Assays to measure transmission-blocking activity
N Assays to measure activity against liver stages
N In vitro culture of P. vivax and other non-falciparum species
for drug screening
N Genomic and proteomic approaches to identify transmis-
sion-blocking and liver-stage activity
KNOWLEDGE GAPS AND RESEARCH PRIORITIES FOR DRUG TREATMENT
AND PREVENTION STRATEGIES FOR ERADICATION
N Field studies to evaluate new drugs and approaches in a
variety of epidemiological settings
N Robust and highly sensitive malaria diagnostics for malaria
infection and especially for carriage of infectious gameto-
cytes
N Measures to monitor and improve adherence and safety
N How must drug treatment and prevention strategies
change as elimination proceeds?
N Strategies to deter resistance
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tion. The rest of this paper considers these areas, which together
make up the draft research and development agenda that we
propose in Box 2. Finally, we also briefly touch on cross-cutting
issues that require coordination with the other malERA groups.
Optimization of the Use of Currently Available
Drugs for Elimination
The time from lead identification of a new compound to a
licensed drug is measured in decades. Thus, the optimization of
existing tools for control and elimination must occur in parallel
with development of new tools for elimination and eradication. As
discussed earlier, one of the assumptions underlying the malERA
process is that global eradication of malaria cannot be accom-
plished with existing tools, but that malaria is being eliminated
from areas with relatively low transmission and relatively good
health systems using these tools. Consequently, in parallel with the
development of new drugs and other eradication tools, research is
needed to optimize drugs that can be used now to reduce malaria
transmission. The first section of Box 2 highlights priority
knowledge gaps and research questions related to currently
available antimalarial drugs. Most of these topics should already
be research priorities irrespective of malaria eradication. They are
highlighted here because they are essential for eradication but
relatively neglected. The most important knowledge gaps relate to
the use of 8-aminoquinolines and ACTs. 8-aminoquinolines are
the only drugs available today that can kill dormant liver stages
and gametocytes. Primaquine, the only currently licensed 8-
aminoquinoline, is routinely used to prevent relapses of P. vivax
and P. ovale and has played a prominent role in several successful
elimination campaigns; the long-acting 8-aminoquinoline tafeno-
quine is not yet licensed. ACTs, which are presently the first-line
treatment for both uncomplicated and severe falciparum malaria
in most of the world, are threatened by the recent emergence of
artemisinin resistance in Southeast Asia [12,29].
Research to optimize the successful use of these drugs to
eliminate malaria from the approximately 30 countries now
actively pursuing this goal represents ‘‘low-hanging fruit’’ that is
likely to yield high gains at relatively low cost over the next 5–10
years. While recognizing that global eradication will require
substantial investment in new tools, the large gains that can be
made and consolidated by making the most of the tools now in
hand should not be underestimated.
The paucity of information about pharmacokinetics, pharma-
codynamics, and rational dosing of drugs represents a critical
knowledge gap that needs to be addressed in order to use current
drugs in conjunction with other tools to reduce malaria
transmission, as well as to provide rationally designed treatment
strategies. The other top priority is the development of robust and
sensitive field diagnostics to guide drug interventions and to detect
carriage of gametocytes that are infectious to mosquitoes. This
type of research is also a priority for vaccine development [30].
Development of New Drugs for Elimination and
Eradication
The second section of Box 2 summarizes key knowledge gaps
and research priorities for the development of new drugs
specifically for elimination and eradication indications. Below,
we discuss some of these issues in more detail. Importantly,
because antimalarial drugs have not previously been licensed for
indications other than individual treatment, early and close
consultation with regulatory authorities will be needed for any
drugs used for elimination and eradication.
Targeting Liver and Sexual Stages and Greater Emphasis
on Safety
In 1957 Wallace Peters wrote, ‘‘Development of an 8-
aminoquinoline in depot form to give a safe and adequate blood
level should be attempted as this would be an invaluable weapon
against malaria if properly applied’’ [31]. More than 50 years
later, the dream of a safe, long-acting drug that eliminates malaria
infection by killing liver stages and that blocks transmission by
killing gametocytes remains both unfulfilled and a top priority. As
mentioned earlier, the only known antimalarial drugs that kill
dormant liver stages and gametocytes are the 8-aminoquinolines
primaquine and tafenoquine. Both of these drugs have a serious
flaw for a drug that would be used to eliminate infection and block
transmission in people who are not themselves acutely sick with
malaria—they cause hemolysis (destruction of red blood cells
leading to anemia) in individuals with glucose-6-phosphate
dehydrogenase (G6PD) deficiency, a red cell polymorphism that
is common in tropical populations because it is associated with
some degree of protection against malaria illness [32]. Any drug
used for malaria elimination in people who are not sick must have
a low risk-to-benefit ratio akin to the low risk-to-benefit ratios of
routine immunizations.
During its brainstorming sessions, the malERA drugs group
developed draft target product profiles (TPPs) for new drugs that
could be used for radical cure (including elimination of both liver
stages and gametocytes) of P. falciparum and P. vivax. These TPPs
(see Tables S1–S3) represent the ideal targets and a starting point
for discussion with drug developers. Drugs that fall short of these
ideals will still be of value for eradication, and adjudicating
between the ideal and the acceptable will be a dynamic and
continuous process. For example, the ideal drug would target all
malaria species, but it would not be prudent to reject promising
candidates that target only P. falciparum or P. vivax. Indeed,
depending on leads and progress, it is likely to be necessary to
pursue at least partly separate research agendas for these two key
species.
Ideal Pharmacokinetic/Pharmacodynamic Characteristics
An ideal eradication drug would have a short half life with a
sustained (depot-like) release followed by rapid elimination, and
would be deployed in combination with other drugs with matching
pharmacokinetic and pharmacodynamic profiles both to deter
resistance and to improve efficacy [13]. Such characteristics would
allow for rapid onset of action to exert quick killing, long duration
of action to permit administration in a single encounter at
infrequent intervals, and rapid clearance to avoid a long period of
sublethal drug levels conducive to selection for resistant parasites.
An intermediate goal may be to develop a safe product for delivery
at a single encounter of a curative dose of a drug that also offers 4
or more weeks of post-treatment causal prophylactic efficacy.
Antimalarial drugs with half lives in the range of weeks are
already available but do not offer the ideal pharmacokinetic/
pharmacodynamic profile of sustained or intermittent pulsed
killing levels followed by rapid drop-off to deter resistance.
Previous research on polymers for pulsed release of malaria
vaccines showed initial promise but was abandoned by WHO.
Nanotechnology may offer another approach for developing drugs
with the ideal pharmacokinetic/pharmacodynamic profile. Nano-
particle delivery of drugs and vaccines is in the early stages of
development, and one challenge for this form of delivery is the
limitation on the dose of drug that can be delivered. Highly potent
PLoS Medicine | www.plosmedicine.org 6 January 2011 | Volume 8 | Issue 1 | e1000402drugs that require a low dose would therefore be most attractive
for this delivery method. Subcutaneous implants such as those
used to deliver birth control drugs also warrant consideration.
The malERA drugs group felt strongly that concerns of
impracticality and expense should not deter research into the
ideal pharmacokinetic/pharmacodynamic profile. Seemingly risky
approaches can and should be entertained in the quest for
solutions and evaluated for their potential. Speculation about the
ultimate cost of an intervention should not be the sole basis for its
rejection from further consideration.
In some circumstances, these ideal pharmacokinetic/pharma-
codynamic characteristics may be less critical, such as when drugs
are administered in settings or at times when there is very low or
no transmission. A specific example of this is the use of mass
treatment to eliminate the infectious reservoir at the nadir of
malaria transmission in settings with sharply seasonal malaria
transmission. Because there is a very low probability of parasites
encountering subtherapeutic drug levels in this setting, there may
be little disadvantage to drug combinations with mismatched
pharmacokinetic/pharmacodynamic profiles. This example high-
lights the importance of considering setting-specific epidemiology
and indications when thinking about desired characteristics of
drugs for elimination and supports the idea of tailoring TPPs to
specific indications on the basis of the parasites, human
populations, epidemiological settings, and stages of elimination
and eradication that are to be targeted.
Drug Resistance
It has been suggested that concerns about drug resistance and
strategies to deter it—for example, the obligatory use of
combinations of drugs with different mechanisms—may not be a
priority in the context of malaria eradication, because resistance is
unlikely to emerge and spread when transmission is very low in the
late stages of elimination. However, evidence suggests that drug
resistance can spread rapidly and become fixed in populations in
settings of low malaria transmission [33], and history amply
demonstrates the folly of counting on the efficacy of drugs to
endure in the face of widespread use [3]. Even at ‘‘the last mile,’’
when eliminating the last few cases of malaria from an area, the
risk of exporting malaria to, or reintroducing it from, other
malarious areas will remain. This risk will only disappear during
the final stages of global eradication when remaining foci are very
few and far between. For these reasons, it is important that the
development process for drugs and drug combinations for
elimination and eradication indications should attempt to build
in strategies for preventing and deterring resistance. These
strategies include combining drugs with different mechanisms of
action [34] or even drugs with opposing resistance mechanisms,
and coformulation of drugs.
Clinical Research
The current capacity for conducting both laboratory and
clinical malaria pharmacokinetics/pharmacodynamics studies is
very limited. Consequently, most antimalarial drugs are used in
risk groups and populations for whom there is little to no
information on optimal dosing for efficacy and safety. Careful and
rigorous clinical pharmacology studies will be needed for new
drugs and drug combinations for eradication, and robust methods
instituted for postlicensure marketing surveillance for side effects.
This research will require expanded capacity for drug level
measurements, pharmacokinetics analysis and clinical pharmacol-
ogy studies, and surveillance. As malaria incidence falls at
established malaria research sites, it is already becoming
increasingly difficult to meet sample size requirements for drug
efficacy trials. It may, therefore, become necessary to establish
mobile clinical trial networks or novel clinical trials designs (for
example, field trials in malaria-exposed populations that measure
gametocyte prevalence and infectivity) to assess the efficacy of
drugs for blocking transmission and preventing relapse and/or to
rely more on the use of experimental malaria challenge studies
[35] to evaluate drugs (and vaccines) for eradication.
Drug Treatment and Prevention Strategies for
Eradication
Although much can be learned from careful review of the role
played by drugs in past elimination programmes, creatively
designed prospective field research and pilot projects and
operational research to assess interventions as they are imple-
mented in different settings will be essential for the success of
malaria eradication (see the final section of Box 2). That is,
research is needed to understand when, where, and how to use
drugs to eliminate and eradicate malaria. For example, current
guidelines do not recommend MDA, and evidence from field
studies of the efficacy of specific interventions in specific
populations and epidemiological settings is needed to support a
change in this recommendation. Thus, the effectiveness of mass
screening and treatment of only infected individuals needs to be
compared with treating all individuals irrespective of whether they
are infected, as is done in MDA. Similarly, the effectiveness of
‘‘focal screening and treatment,’’ (a variation on mass screening
and treatment that uses molecular diagnostics to identify the
individuals to be given curative treatment) that is now being used
in an attempt to contain emerging artemisinin-resistant falciparum
malaria in western Cambodia [36] needs to be properly evaluated.
Furthermore, research is needed into the different drug
treatment and prevention strategies that will be needed for
different epidemiological settings at different stages of the
elimination process, and in settings with different levels of health
care infrastructure. Drug treatment and prophylaxis schemes that
are feasible and effective in stable rural populations with year-
round malaria transmission may be completely ineffective if
implemented in a setting with highly seasonal malaria, or
impossible in mobile populations or in areas of civil unrest.
Moreover, as transmission rates decline, so will levels of protective
immunity, resulting in fewer cases of infection spread across a
wider range of age groups. As reduced transmission is sustained for
years, asymptomatic carriage will become increasingly uncom-
mon, making MDA less attractive [37].
Research is also needed into robust and sensitive screening tests
to guide drug treatment and prophylaxis both for asexual parasites
and for infectious gametocytes and to evaluate the efficacy of drugs
(and vaccines) that are intended to block transmission. The current
gold standard, light microscopy, is insufficiently sensitive to detect
low levels of gametocytes that are nevertheless capable of being
transmitted, and current investigational assays that offer improved
sensitivity are not robust enough for field surveillance in most
settings, nor are they validated as predictive of infectivity.
Cross-Cutting Issues
Several important knowledge gaps and research priorities for
drug strategies cut across one or more of the technical areas
covered by malERA. For example, for any malaria research
enterprise to succeed, it is essential to engage scientists in endemic
countries to identify, prioritize, and refine research questions and
to design the most appropriate approaches. This process is
particularly important for research involving human-based
interventions such as drugs, because issues like population
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on drug efficacy and safety require knowledge of local cultural,
political, ecological, and epidemiological factors. Other examples
of cross-cutting research issues include research into health systems
and how they deliver malaria interventions, operational research,
malaria modeling and research into monitoring and surveillance,
vaccines, and vector control. These cross-cutting issues are
addressed in the other malERA papers in this series [30,37–40].
Concluding Remarks
The potential list of research priorities for developing and using
drugs to eradicate malaria is as long as the list of research
interests of the individuals who participated in the consultative
process. To be useful in setting a research agenda for eradication,
however, the list must be focused and prioritized. This report
focuses on research goals that will be achieved largely in the
longer term, and these suggestions are passed to the rest of the
malaria community in the form of a draft research and
development agenda (Box 2) with a sincere request that the
whole of the malaria community uses its considerable wisdom
and experience to improve this agenda in the spirit of a shared
hope for a malaria-free future.
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